{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:43:21Z","timestamp":1786653801940,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study aims to investigate the factors associated with breast cancer brain metastasis (BCBM) in individuals suffering from breast cancer (BC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This cross-sectional study conducted on 200 patients with metastatic breast cancer (MBC) including 52 brain and 148 other organ metastases. The demographic, medical, clinical, laboratory, and therapeutic approach characteristics were compared between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Headache (61.5%), weakness and lethargy (26.9%), dizziness (15.4%), blurred vision\/blindness (15.4%), and convulsions (15.4%) were the major initial symptoms of BCBM. Radiotherapy (71.2%), injectable (34.6%), and oral chemotherapy (26.9%) were the major applied therapeutic strategies to manage brain metastasis (BM). The overall survival of the patients from cancer diagnosis to death accounted for 33 months (95%CI: 27.52\u201338.47), while this period after BM diagnosis was limited to 6 months (95%CI: 5.15\u20136.84). The rate of hormone therapy was remarkably higher among the metastasis in other organs than the brain (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.005), while targeted therapy was performed in higher rates for BM (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.001). The evaluation of BC-related tumor markers revealed that human epidermal growth factor 2 (HER2) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.001) positivity was remarkably higher among BCBM, while positive estrogen receptor (ER) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.004) and progesterone receptor (PR) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.013) were statistically more in the other group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on the findings of this study, the BC patients with BM had a remarkable short survival, had a higher rate of perineural invasion, and were mostly positive for HER2. Radiotherapy, chemotherapy, and surgery were the most common approaches to these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/abr.abr_262_24","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:23:11Z","timestamp":1743351791000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of Prevalence, Survival, and Molecular Type of Breast Cancer Patients with Brain Metastases"],"prefix":"10.4103","volume":"14","author":[{"given":"Amir","family":"Aria","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Cancer Prevention Research Center Seyyed Al-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Sharifi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Cancer Prevention Research Center Seyyed Al-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setayesh","family":"Sindarreh","sequence":"additional","affiliation":[{"name":"Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3]]},"reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-021-01424-8","article-title":"Breast cancer brain metastasis: Insight into molecular mechanisms and therapeutic strategies","volume":"125","author":"Wang","year":"2021","journal-title":"Br J Cancer"},{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: A systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","article-title":"Treatment strategies for breast cancer brain metastases","volume":"124","author":"Bailleux","year":"2021","journal-title":"Br J Cancer"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-020-1140-x","article-title":"microRNAs orchestrate pathophysiology of breast cancer brain metastasis: Advances in therapy","volume":"19","author":"Kanchan","year":"2020","journal-title":"Molecular cancer"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"1758835920936151.","DOI":"10.1177\/1758835920936151","article-title":"Emerging treatment strategies for breast cancer brain metastasis: From translational therapeutics to real-world experience","volume":"12","author":"Ren","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1172\/JCI91553","article-title":"JAK2-binding long noncoding RNA promotes breast cancer brain metastasis","volume":"127","author":"Wang","year":"2017","journal-title":"J Clin Invest"},{"key":"R8-20250328","first-page":"159","article-title":"Cancer statistics in IR Iran in 2020","volume":"12","author":"Zendehdel","year":"2020","journal-title":"Basic Clin Cancer Res"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"1078.","DOI":"10.3390\/cancers13051078","article-title":"Breast cancer brain metastasis\u2014overview of disease state, treatment options and future perspectives","volume":"13","author":"Watase","year":"2021","journal-title":"Cancers"},{"key":"R10-20250328","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10552-011-9859-8","article-title":"Factors associated with mortality after breast cancer metastasis","volume":"23","author":"Jung","year":"2012","journal-title":"Cancer Causes Control"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"e2653.","DOI":"10.6061\/clinics\/2021\/e2653","article-title":"Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis","volume":"76","author":"Bai","year":"2021","journal-title":"Clinics"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2018.0813","article-title":"Implications of screening for brain metastases in patients with breast cancer and non\u2013small cell lung cancer","volume":"4","author":"Cagney","year":"2018","journal-title":"JAMA Oncol"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours*","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"R14-20250328","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijrobp.2017.04.037","article-title":"A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 study update): Irradiation-related complications and long-term maintenance of mini-mental state examination scores","volume":"99","author":"Yamamoto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20250328","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3\u00d79 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: A comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20250328","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"R17-20250328","first-page":"6","article-title":"Innovative approaches for breast cancer metastasis to the brain","author":"Klaas","year":"2022","journal-title":"Arch. Med. Case Rep. Case Stud"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"208.","DOI":"10.21873\/cdp.10203","article-title":"Perineural invasion predicts unfavorable prognosis in patients with invasive breast cancer","volume":"3","author":"Hosoya","year":"2023","journal-title":"Cancer Diagn Progn"},{"key":"R19-20250328","doi-asserted-by":"crossref","first-page":"12333","DOI":"10.1007\/s00432-023-05125-y","article-title":"Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer","volume":"149","author":"Wu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.breast.2012.12.006","article-title":"Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era","volume":"22","author":"Olson","year":"2013","journal-title":"Breast"},{"key":"R21-20250328","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaoncol.2017.0001","article-title":"Brain metastases in newly diagnosed breast cancer: A population-based study","volume":"3","author":"Martin","year":"2017","journal-title":"JAMA Oncol"},{"key":"R22-20250328","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11060-017-2549-y","article-title":"Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development","volume":"134","author":"Saraf","year":"2017","journal-title":"J Neurooncol"},{"key":"R23-20250328","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-014-3090-8","article-title":"Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: A multicenter retrospective analysis","volume":"147","author":"Niikura","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R24-20250328","doi-asserted-by":"crossref","first-page":"2705.","DOI":"10.1038\/s41467-018-05030-w","article-title":"Reactive astrocytic S1P3 signaling modulates the blood\u2013tumor barrier in brain metastases","volume":"9","author":"Gril","year":"2018","journal-title":"Nat Commun"},{"key":"R25-20250328","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-017-4279-4","article-title":"Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis","volume":"164","author":"Lewis Phillips","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"R26-20250328","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-17-3351","article-title":"Drug resistance in HER2-positive breast cancer brain metastases: Blame the barrier or the brain?","volume":"24","author":"Kabraji","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R27-20250328","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr\u2010trastuzumab and PET imaging of HER2\u2010positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R28-20250328","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","article-title":"64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer","volume":"54","author":"Tamura","year":"2013","journal-title":"J Nucl Med"},{"key":"R29-20250328","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R30-20250328","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-019-05317-6","article-title":"Breast leptomeningeal disease: A review of current practices and updates on management","volume":"177","author":"Figura","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"R31-20250328","doi-asserted-by":"crossref","first-page":"2610.","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"R32-20250328","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"R33-20250328","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: Exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial*","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"key":"R34-20250328","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"key":"R35-20250328","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-08-1080","article-title":"Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R36-20250328","article-title":"Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC)","author":"Lin","year":"2017","journal-title":"J Clin Oncol"},{"key":"R37-20250328","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","article-title":"Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"R38-20250328","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000512212","article-title":"Prognostic factors and survival outcomes among patients with breast cancer and brain metastases at diagnosis: A national cancer database analysis","volume":"99","author":"Zimmerman","year":"2021","journal-title":"Oncology"},{"key":"R39-20250328","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12282-017-0753-4","article-title":"Specific sites of metastases in invasive lobular carcinoma: A retrospective cohort study of metastatic breast cancer","volume":"24","author":"Inoue","year":"2017","journal-title":"Breast Cancer"},{"key":"R40-20250328","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.humpath.2017.03.022","article-title":"Clinicopathological factors associated with survival in patients with breast cancer brain metastasis","volume":"64","author":"Li","year":"2017","journal-title":"Hum Pathol"}],"container-title":["Advanced Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_262_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:33Z","timestamp":1786650153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/abr.abr_262_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/abr.abr_262_24","relation":{},"ISSN":["2277-9175"],"issn-type":[{"value":"2277-9175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}